Sage Journals: Discover world-class research

Abstract

In 2007, the US Food and Drug Administration (FDA) and Pfizer Inc recommended immediate discontinuation of nelfinavir (NFV) during pregnancy due to contamination with a potential teratogen. A few weeks after the announcement, we surveyed antenatal HIV care providers to determine how widely the warning was disseminated. Overall, 69 of 121 (57.0%) providers knew to discontinue NFV. Callers with more than 50 HIV-infected patients were 2.54 times as likely to be aware as callers with 1-3 HIV-infected patients (P < .01). Only 12 (33.3%) obstetricians were aware, compared to 21 (80.8%) infectious diseases specialists (P < .001). The FDA/Pfizer Inc recommendation to avoid nelfinavir mesylate (NFV) in pregnancy appears to have successfully reached HIV experts. However, not all pregnant women have access to experts and may receive most of their care from providers without extensive HIV experience. More effective dissemination of critical HIV-related information to all antenatal care providers, including general obstetricians, family physicians, and midwives, may be needed.

Keywords

ethyl methanesulfonate nelfinavir perinatal pregnancy teratogen

References

Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep . 1998;47(RR-2):1-30.

Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. October 12, 2006. http://aidsinfo.nih.gov/Guidelines . Accessed February 4, 2009.

Federal Drug Administration. Nelfinavir (marketed as Viracept) Impurity and Potential Shortage Information. http://www.fda.gov/cder/drug/infopage/nelfinavir/default.htm. Accessed February 4, 2009.

Sega GA A review of the genetic effects of ethyl methanesulfonate. Mutat Res. 1984;134(2-3):113-142.

Federal Drug Administration. MedWatch, The FDA Safety Information and Adverse Event Reporting Program. 2007 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. http://www.fda.gov/medwatch/safety/2007/safety07.htm#Viracept . Accessed February 4, 2009.

Pfizer Inc. VIRACEPT1 (nelfinavir mesylate) 250 mg, 625 mg tablets, and Powder for Oral Suspension. Important Information for Prescribers. September 10, 2007 . http://www.fda.gov/medwatch/safety/2007/VIRACEPT_HCPLetter_9_10_07.pdf . Accessed February 4, 2009.

Department of Health and Human Services Perinatal Panel. Notice on Nelfinavir FDA-Pfizer Letter- September 11, 2007. http://aidsinfo.nih.gov/contentfiles/PeriNFVNotice.pdf . Accessed February 4, 2009.

Fogler JA , Weber S. , Goldschmidt RH , et al. Consultation needs in perinatal HIV care: experience of the National Perinatal HIV Consultation Service. Am J Obstet Gynecol . 2007;197(3 suppl):S137-S141.

Pfizer Inc. VIRACEPT1 (nelfinavir mesylate) 250 mg, 625 mg tablets, and Powder for Oral Suspension. Important Information for Prescribers. May 6, 2008. http://www.viracept.com/pdf/VIRACEPT_HCPLetter_5_6_08.pdf. Accessed February 4, 2009.

Clinicians' Knowledge of 2007 Food and Drug Administration Recommendation to Discontinue Nelfinavir Use During Pregnancy

Abstract

Keywords

References